If you or someone you love is taking a compounded version of semaglutide (the active ingredient in Ozempic and Wegovy) or tirzepatide (the active ingredient in Mounjaro and Zepbound), you have probably seen the headlines this month. On April 30, the U.S. Food and Drug Administration formally proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B “bulks list,” a regulatory move that could dramatically reduce the supply of compounded GLP-1 medications in the United States. The public comment window closes June 29, 2026, and patients here in Statesboro and across Bulloch and Toombs Counties are asking us at the pharmacy counter what this means for them.

This is one of those moments where the news is moving fast and the rumors are moving faster. So let’s slow down, look at what the FDA actually said, and talk through what we know — and what we don’t.

What the FDA Actually Proposed

Section 503B of the Federal Food, Drug, and Cosmetic Act allows large outsourcing facilities to compound drugs from bulk active ingredients only when those ingredients are on a specific approved list or when there is a documented clinical need. According to the Federal Register notice published May 1, 2026, the FDA has tentatively concluded there is “no clinical need” to include semaglutide, tirzepatide, or liraglutide on that list now that the branded products are no longer in shortage.

Semaglutide was removed from the FDA shortage list in 2025, and tirzepatide was removed in 2024. With the shortage resolved and the bulks list door closing, both of the legal pathways that allowed industrial-scale compounding of these molecules would be effectively shut. The agency is accepting written comments through the federal docket until June 29, 2026, and will issue a final determination after that.

Why the FDA Is Concerned About Compounded GLP-1s

Compounded GLP-1 medications became enormously popular during the 2022–2024 shortages, in part because they were dramatically cheaper. As Medical News Today reported, compounded versions ran roughly $200 to $400 per month while branded Wegovy listed near $1,349 and Zepbound’s direct-to-consumer program around $1,086 for lower doses. At the 2024 peak, compounded GLP-1s reached an estimated 30% of total U.S. supply.

But the savings came with safety questions. The FDA has reported more than 455 adverse event reports tied to compounded semaglutide and more than 320 reports tied to compounded tirzepatide as of early 2025, according to coverage in Pharmacy Times. Many of those incidents involved patients drawing the wrong dose from multidose vials, and some required hospitalization. The agency has also flagged cases where compounders used unapproved salt forms of semaglutide whose safety and efficacy have never been established in clinical trials.

It is worth being clear: compounding pharmacies serve a real, important role in patient care. The FDA’s concern is specifically with large-scale, mass-produced compounded versions of complex injectable peptides, not with patient-specific compounding done for medical necessity under a prescriber’s direction.

What This Could Mean for Patients

If the proposal is finalized, the most immediate effect would be a sharp decline in the availability of compounded semaglutide and tirzepatide through the telehealth and cash-pay clinics that have dominated the market. Some patients would shift to the FDA-approved branded products. Others may look at the newer oral options — Novo Nordisk’s oral Wegovy (semaglutide pill) and Eli Lilly’s Foundayo (orforglipron), both of which received FDA approval over the past several months. Foundayo’s lowest doses start at $149/month for cash-pay patients under a recent pricing deal, which is a meaningful change in the affordability picture.

There is no need to panic-stop a medication today. Nothing changes immediately. But this is a good moment to know what you’re taking, where it’s coming from, and what your plan is if access changes later this year.

A Pharmacist’s Perspective

Here’s what I would tell you if you walked up to the counter at one of our four locations in Statesboro, Brooklet, or Lyons. I am cautious about compounded versions of complex biologic-like peptides such as semaglutide and tirzepatide, and I have been for a while. The FDA-approved versions are made under tight quality controls, are dosed in pre-measured pens, and have been studied in tens of thousands of patients. Compounded versions vary by facility, sometimes vary by lot, and the dosing math is on the patient. That is a real difference.

That doesn’t mean compounded medications are bad, and it doesn’t mean every compounded GLP-1 patient has had a bad experience. Many have not. But when the price of admission to a cheaper option is “you draw your own dose from a vial,” that’s a different kind of decision than picking up a pre-filled pen.

If you’re on a compounded GLP-1 right now, the most useful thing you can do is talk to your prescriber about a contingency plan: what would your transition to a branded or oral GLP-1 look like, what would it cost on your insurance, and is your dose appropriate for the conversion? Your pharmacist can help you walk through that — that’s exactly the kind of conversation we’re built for.

Frequently Asked Questions

Is compounded semaglutide illegal now?

No. The FDA’s May 2026 announcement is a proposal, not a final rule. Public comments are open through June 29, 2026, and any final action would come after that. For now, current rules still apply.

What is the 503B bulks list?

It is the list of bulk drug substances that 503B outsourcing facilities are permitted to use for large-scale compounding because the FDA has determined there is a clinical need. If a substance is not on the list and is not in shortage, large-scale compounding of it is not permitted.

Will my Walker Pharmacy prescription be affected?

If you fill a brand-name, FDA-approved GLP-1 medication with us — Ozempic, Wegovy, Mounjaro, Zepbound, the new oral Wegovy, or Foundayo — the proposed rule does not change anything about that prescription. If you currently get a compounded version from a telehealth provider or another source, it’s worth bringing the bottle and your prescription to a pharmacist to review.

Are the new GLP-1 pills as effective as the injections?

Oral semaglutide and orforglipron have both demonstrated meaningful weight loss in clinical trials, though head-to-head results vary by dose and by patient. The trial data is still maturing. Your prescriber is the right person to discuss which option fits your specific situation.

How can I tell if my GLP-1 medication is FDA-approved or compounded?

FDA-approved branded products come in a sealed pen or pre-filled syringe with a manufacturer’s label (Novo Nordisk or Eli Lilly), a National Drug Code, and an FDA-approved patient information leaflet. Compounded versions typically come in vials with a compounding pharmacy’s label. If you’re unsure, bring it by — we can help you identify it.

Come Talk to Us

Independent pharmacy is built for moments like this. Rules change. Supply chains shift. Headlines get ahead of the facts. Your local pharmacist is the person who can sit down with your medication list, your insurance plan, and your prescriber’s notes and help you figure out what actually applies to you. If you would like to consolidate your prescriptions with a pharmacy that knows you by name, you can transfer your prescriptions to Walker Pharmacy in a few minutes — we handle the paperwork on our end.

This article is for informational purposes only and does not constitute medical or health advice. Always consult your physician or pharmacist before making changes to your health regimen.

— Jordan Walker, PharmD | Owner, Walker Pharmacy